How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

187 results for

Vulvar Dermatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Labial fusion: A rare cause of urinary retention in reproductive age woman and review of literature (PubMed)

Labial fusion: A rare cause of urinary retention in reproductive age woman and review of literature Labial fusion usually affects prepubertal girls and postmenopausal women, it may rarely occurs in reproductive years in the absence of predisposing factors such as vulvar infections, dermatitis, trauma, female circumcision and lichen sclerosis. Should be considered in differential diagnosis in the differential diagnosis of urinary retention even if the patient doesn't have history of sexual

Full Text available with Trip Pro

2017 Turkish journal of urology

42. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

neuronsinthevagina.Thisfunctionmayservetodecreasethe discomfort associated with VVA. 11 The term vulvovaginal atrophy refers specifically to the changes in the vaginal and vulvar surfaces that on examina- tion arethin,pale,anddry.Thevaginacannarrowandshorten, and the introitus may constrict, especially in the absence of penetrative sexual activity. The vaginal lining may exhibit petechiae and become thinner (often only a few cell layers thick),lesselastic,andprogressivelysmootherasrugalfolds decrease. Vaginal blood flow diminishes. Although (...) ability to have pain-free sexual activity. 33<36 Dyspareunia has been shown to be strongly associated with female sexual dysfunction in postmeno- pausal women. 31 Decreased genital arousal and vulvar pain disorders may occur as a consequence of VVA. Atrophy and phimosis of the prepuce of the clitoris may result in dyspareuniathatleads todecreasedinterestinandavoidance of sexual activity. 37 In these scenarios, dyspareunia or avoid- ance of sexual activity may be a presentation of VVA. Vulvar

2013 The North American Menopause Society

44. TOL-463 Phase 2 Study for Vaginitis

, or contact dermatitis involving the vulvar epithelium. Presence of T. vaginalis on wet mount or evidence of other infectious cause of cervicitis or vaginitis on physical examination. Active genital lesions, including ulcers, vesicles consistent with herpes, or warts. Use of metronidazole or other 5-nitro-imidazole derivative or clindamycin or an antifungal agent (intravaginal or systemic) for the treatment of any condition within 14 days of start of study. Planned ongoing immunosuppressive therapy (...) the course of the trial. e.g., antifungal preparations, deodorant sprays, spermicides, contraceptive creams, gels, foams, sponges Participant is willing to refrain from using tampons and diaphragms for the seven days of the study product use. Exclusion Criteria: A diagnosis of vaginitis other than BV or VVC or another vaginal or vulvar condition* that might confuse interpretation of response to study product. Examples of such conditions include erosive lichen planus, desquamative interstitial vaginitis

2016 Clinical Trials

45. The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia

Inclusion Criteria: A history of 3 months or more of vulvar pain suggestive of PVD, i.e. symptoms of pain on vaginal penetration (insertional dyspareunia and/or pain with tampon insertion). On exam, tenderness localized within the vestibule when being touched with a cotton-tip applicator. No identifiable cause for the pain, such as vulvovaginal candidiasis, vaginal atrophy, desquamative inflammatory vaginitis (DIV), herpes, dermatitis or vulvar dystrophy. Exclusion Criteria: other causes for vulvar pain (...) by touching the vestibule with a cotton-tip applicator in 6 defined points (2,5,6,7, 10 and 12),while the patient is being asked to rate the intensity of pain verbally from 0 to 10 at each point. Secondary Outcome Measures : Measurement of vestibular tenderness using a vulvar algesiometer [ Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months. ] Change of pain using Visual analog scale [ Time Frame: Change in VAS between recruitment to 3 months, 6 months , 9 months and 12

2016 Clinical Trials

46. Subtypes of Provoked Vestibulodynia

Inclusion Criteria: A history of 3 months or more of vulvar pain suggestive of PVD, i.e. symptoms of pain on vaginal penetration (insertional dyspareunia and/or pain with tampon insertion). On exam, tenderness localized within the vestibule when being touched with a cotton-tip applicator. No identifiable cause for the pain, such as vulvovaginal candidiasis, vaginal atrophy, desquamative inflammatory vaginitis (DIV), herpes, dermatitis or vulvar dystrophy. Exclusion criteria: other causes for vulvar pain (...) recruitment to 3 months, 6 months 6 months, 9 months and 12 months ] The exam is performed by touching the vestibule with a cotton-tip applicator in 6 defined points (2,5,6,7, 10 and 12),while the patient is being asked to rate the intensity of pain verbally from 0 to 10 at each point. Secondary Outcome Measures : Visual analog scale (VAS) [ Time Frame: Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months ] Measurement of vestibular tenderness using a vulvar algesiometer [ Time Frame

2016 Clinical Trials

47. Vulvodynia

Vulvodynia Vulvodynia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Vulvodynia Vulvodynia Aka: Vulvodynia , Vulvar Pain (...) , Dysesthetic Vulvodynia , Essential Vulvodynia , Vulvar Dysesthesia From Related Chapters II. Definitions Vulvodynia Chronic vulvar discomfort is stinging, burning, and raw No visible dermatoses No identifiable neurologic disorder Erythema may be only finding III. Types Spectrum of Vulvodynia Previously known as Timing Provoked Vulvodynia (triggered by touch) Unprovoked Vulvodynia (continuous Vulvodynia) IV. Symptoms Characteristics Burning, irritating, or sharp pain Timing: Onset with provocation, lasting

2018 FP Notebook

48. Lichen Simplex Chronicus

Simplex Chronicus Aka: Lichen Simplex Chronicus , Lichen Simplex , Circumscribed Neurodermatitis , Lichen Simplex Nuchae , Scalp Picker's Nodule , Vulvar Lichen Simplex Chronicus , Red Scrotum Syndrome From Related Chapters II. Pathophysiology Lichenified skin reaction to chronic scratching (may occur while asleep) III. Causes s (most common) , or Skin cancers Exacerbating factors Heat or excessive sweating Irritation from overlying clothing Topical cleansers, lotions or other products IV. Signs (...) the itch-scratch cycle See s for specific locations Triamcinolone 0.1% ointment twice daily until active dermatitis resolves Advance to Clobetasol 0.05% daily if refractory after 2-3 weeks Consider oral s if still refractory after 2-3 weeks Intertriginous areas (perianal area or behind ear) Triamcinolone 0.1% ointment twice daily until active dermatitis resolves Scalp gel applied twice daily until active lesions resolve Inject intralesional ( 10 mg/ml) for scalp s Consider 20 mg twice daily for 2 weeks

2018 FP Notebook

49. Topical Corticosteroid

(Level 4-5) (vulvar) Nummular Perianal inflammation (severe cases) (only after the anti- agent has been used) Severe Low potency s (Level 6-7) Dermatitis (face, s, diaper area) Perianal inflammation References XIII. Dosing: Corticosteroid Potency Selection by distribution Low potency Topical Corticosteroids Face Groin Intertriginous areas Mid-potency Topical Corticosteroids Thin skin trunk areas Extremity lesions High potency Topical Corticosteroids Thick skin trunk areas Extremity lesions Very high (...) absorption with systemic steroid effects Skin atrophy Rebound papular dermatitis after medium-high potency Avoid high potency steroid on genital or face Striae formation Telangiectasia IV. Example: Lower cost, generic steroids Level 1: Clobetasol Propionate 0.05% ointment (price jump to $200 for 45 g in 2017) Level 2: Betamethasone Dipropionate 0.05% ointment Level 3: Betamethasone Dipropionate 0.05% cream Level 4: Triamcinolone Acetonide 0.1% ointment Level 5: Triamcinolone Acetonide 0.1% ointment Level

2018 FP Notebook

50. Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus

Measures : SkinDEX-29 Score [ Time Frame: Change from baseline score to score at six months ] Validated subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus, described as a total numeric score Secondary Outcome Measures : Number of patients with adverse outcomes [ Time Frame: One year from treatment ] Total number with adverse outcomes to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment Number (...) Posted : October 12, 2015 Last Update Posted : August 17, 2018 See Sponsor: Medstar Health Research Institute Information provided by (Responsible Party): Medstar Health Research Institute Study Details Study Description Go to Brief Summary: This study is being done to compare the effects, good and bad, of fractionated CO2 laser treatment and clobetasol proprionate .05% ointment on vulvar lichen sclerosus. Condition or disease Intervention/treatment Phase Vulvar Lichen Sclerosus Device: Fractionated

2015 Clinical Trials

51. Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes

Sample Study Population Women 18-55 yo with vestibulodynia, and or generalized vulvodynia, characterized by at least 3 months history of pain, burning, or irritation, with an intensity of 4/10 or greater, of the vulva localized to the vestibule (vestibulodynia) with or without pain located in outer region of the vulva (generalized VD). The pain must NOT be attributable to current bacterial, fungal, or yeast infections, a skin condition (eg; dermatitis), hormonal changes, or vaginitis. Criteria (...) , with an intensity of 4/10 or greater of the vulva either localized to the vestibule and precipitated by contact of the vestibule (Provoked VD) or located in other regions of the vulva (called GVD). The pain must not be attributable to dermatitis, dermatosis, candida, hormonal changes, or vaginitis. Generally healthy without current neurological, cardiovascular, hepatic, renal, autoimmune diseases, diabetes or cancer. Willingness to use acceptable contraceptive methods (e.g., hormonal, barrier, or sterilization

2015 Clinical Trials

52. Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis

of an alternative or specific treatment. Not considered as "Treatment Failure": The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1. Patients presenting with only vulvar complaints not considered as related to infectious vaginitis. Secondary Outcome Measures : Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient (...) . suprainfected fungal vaginitis) and able to receive an empirical local treatment Exclusion Criteria: Recurrent patient; i.e. a patient who has had at least 4 episodes of infectious vaginitis in the 12 months prior to inclusion Vaginal infection justifying systemic therapy History of atrophic vaginitis or suspected atrophic vaginitis at inclusion Patient presenting with signs of genital herpes or signs of non-infectious vulvar pathology (vulvodynia, psoriasis, eczema, lichen sclerosus, lichen planus, contact

2015 Clinical Trials

53. Treatment of Prepubertal Labial Adhesions

for eligibility information Ages Eligible for Study: 3 Months to 12 Years (Child) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Prepubertal girls ages 3 months to 12 years with labial adhesions Exclusion Criteria: Presence of underlying dermatologic conditions such as lichen sclerosis, severe atopic dermatitis, psoriasis or vitiligo Presence of systemic conditions that can have vulvar manifestations such as Crohn's disease and Behçet disease Presence of disorders (...) with topical estrogen with lateral traction as compared to an emollient with lateral traction. Condition or disease Intervention/treatment Phase Prepubertal Labial Adhesions Drug: Estradiol cream 0.01% Drug: Cetaphil Not Applicable Detailed Description: The etiology of labial adhesions is unclear but appears to be related to hypoestrogenism in combination with vulvar irritation. For many years, first-line treatment for labial adhesions in prepubertal girls has been topical estrogen. With the use of topical

2014 Clinical Trials

54. VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness

, vulvar vestibulitis dysethetic vulvodynia or vulvar dystrophy, current/chronic papulosquamous vulvar dermatoses (e.g., psoriasis lichen planus, tinea cruris, lichen sclerosis, seborrhea dermatitis, contact or irritant dermatitis, lichen simplex, eczema) or bullous dermatoses or systemic diseases with potential involvement of vulva) Has Irritable Bowel Syndrome or Crohn's Disease Has dyspareunia defined as recurrent or persistent painful intercourse that affects sexual activity Has been in another (...) , radiation therapy, or pelvic floor physical therapy Has an implantable pacemaker, an automatic implantable cardioverter/defibrillator (AICD), or any other implantable electrical device, as these devices may be adversely affected by radiofrequency fields or current Has undergone the Viveve Procedure previously Has medical condition that in investigator's opinion may interfere with wound healing response Has an acute or a chronic vaginal or vulvar disorder (e.g., vaginal atrophy, pain including vulvodynia

2014 Clinical Trials

55. Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients

Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients must be ≥ 18 years of age. Patient with newly diagnosed or recurrent, histologic diagnosis of any of the following tobacco related malignancies: Lung or Bronchus cancer or Head & Neck, cancers (all sites). Esophagus, Stomach, Pancreas, Kidney, Urinary Bladder, Colon, Rectum, Cervix, Vulvar, Vaginal Carcinoma in situ undergoing definitive surgical (...) of Bipolar disorder. Currently taking Bupropion for depression. Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks. History of eating disorder such as anorexia or bulimia. Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis History of epilepsy or seizure disorder. Active severe kidney or liver disease. Women must not be pregnant or lactating. Women of reproductive-potential must have negative serum or urine pregnancy test within 7 days prior

2014 Clinical Trials

57. Nonneoplastic Epithelial Disorders of the Vulva (Overview)

the following: Lichen sclerosus Squamous cell hyperplasia (with and without atypia) (localized neurodermatitis) Primary irritant dermatitis Fixed drug eruption Reiter disease Lupus erythematosus Darier disease Aphthosis and Behçet disease Pyoderma gangrenosum Plasma cell vulvitis Vulvar vestibulitis Blistering diseases involving the vulvar region include the following: Familial benign chronic pemphigus (Hailey-Hailey disease) Pigmentary changes involving the vulvar region include the following (...) -scratch-itch cycle. The initial stimulus to itch may be underlying seborrheic dermatitis, intertrigo, tinea, or psoriasis; however, in most cases, the underlying cause is not evident and may have been transient vulvitis or vaginal discharge. [ ] Any itching disease of the vulva may become secondarily lichenified. Primary irritant dermatitis In the absence of any immune reactivity, this condition is a common cause of vulvar burning and pruritus due to irritation. Chemical agents that remove surface

2014 eMedicine.com

58. Basal Cell Carcinoma (Follow-up)

for nonfacial tumors. RT also is contraindicated in patients with connective tissue diseases or genetic conditions predisposing to skin cancer (eg, xeroderma pigmentosum, epidermodysplasia verruciformis, and basal cell nevus syndrome.) This histologic type in conjunction with RT may induce more tumors in the treated area. Radiation adverse effects include dermatitis, keratinization of the conjunctiva, and chronic keratitis. Cosmetic results are generally good to excellent, with a small amount (...) . . Kara M, Colgecen E, Yildirim EN. Vulvar basal cell carcinoma. Indian J Pathol Microbiol . 2012 Oct-Dec. 55 (4):583-4. . . Newman JC, Leffell DJ. Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg . 2007 Aug. 33(8):957-64; discussion 965. . Karagas MR, Gossai A, Pierce B, Ahsan H. Drinking Water Arsenic Contamination, Skin Lesions, and Malignancies: A Systematic Review of the Global Evidence. Curr Environ Health Rep . 2015 Mar. 2 (1):52-68

2014 eMedicine.com

59. Basal Cell Carcinoma, Eyelid (Follow-up)

for nonfacial tumors. RT also is contraindicated in patients with connective tissue diseases or genetic conditions predisposing to skin cancer (eg, xeroderma pigmentosum, epidermodysplasia verruciformis, and basal cell nevus syndrome.) This histologic type in conjunction with RT may induce more tumors in the treated area. Radiation adverse effects include dermatitis, keratinization of the conjunctiva, and chronic keratitis. Cosmetic results are generally good to excellent, with a small amount (...) . . Kara M, Colgecen E, Yildirim EN. Vulvar basal cell carcinoma. Indian J Pathol Microbiol . 2012 Oct-Dec. 55 (4):583-4. . . Newman JC, Leffell DJ. Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg . 2007 Aug. 33(8):957-64; discussion 965. . Karagas MR, Gossai A, Pierce B, Ahsan H. Drinking Water Arsenic Contamination, Skin Lesions, and Malignancies: A Systematic Review of the Global Evidence. Curr Environ Health Rep . 2015 Mar. 2 (1):52-68

2014 eMedicine.com

60. Basal Cell Carcinoma (Follow-up)

for nonfacial tumors. RT also is contraindicated in patients with connective tissue diseases or genetic conditions predisposing to skin cancer (eg, xeroderma pigmentosum, epidermodysplasia verruciformis, and basal cell nevus syndrome.) This histologic type in conjunction with RT may induce more tumors in the treated area. Radiation adverse effects include dermatitis, keratinization of the conjunctiva, and chronic keratitis. Cosmetic results are generally good to excellent, with a small amount (...) . . Kara M, Colgecen E, Yildirim EN. Vulvar basal cell carcinoma. Indian J Pathol Microbiol . 2012 Oct-Dec. 55 (4):583-4. . . Newman JC, Leffell DJ. Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg . 2007 Aug. 33(8):957-64; discussion 965. . Karagas MR, Gossai A, Pierce B, Ahsan H. Drinking Water Arsenic Contamination, Skin Lesions, and Malignancies: A Systematic Review of the Global Evidence. Curr Environ Health Rep . 2015 Mar. 2 (1):52-68

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>